HK1057042A1 - Tetrahydropyridino or piperidino heterocyclic derivatives - Google Patents

Tetrahydropyridino or piperidino heterocyclic derivatives

Info

Publication number
HK1057042A1
HK1057042A1 HK03109322A HK03109322A HK1057042A1 HK 1057042 A1 HK1057042 A1 HK 1057042A1 HK 03109322 A HK03109322 A HK 03109322A HK 03109322 A HK03109322 A HK 03109322A HK 1057042 A1 HK1057042 A1 HK 1057042A1
Authority
HK
Hong Kong
Prior art keywords
tetrahydropyridino
heterocyclic derivatives
piperidino
piperidino heterocyclic
derivatives
Prior art date
Application number
HK03109322A
Other languages
English (en)
Inventor
Atsuro Nakazato
Toshihito Kumagai
Taketoshi Okubo
Kazuya Kameo
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of HK1057042A1 publication Critical patent/HK1057042A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK03109322A 2000-07-05 2003-12-23 Tetrahydropyridino or piperidino heterocyclic derivatives HK1057042A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000204021 2000-07-05
JP2000270535 2000-09-06
PCT/JP2001/005806 WO2002002549A1 (en) 2000-07-05 2001-07-04 Tetrahydropyridino or piperidino heterocyclic derivatives

Publications (1)

Publication Number Publication Date
HK1057042A1 true HK1057042A1 (en) 2004-03-12

Family

ID=26595443

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03109322A HK1057042A1 (en) 2000-07-05 2003-12-23 Tetrahydropyridino or piperidino heterocyclic derivatives

Country Status (25)

Country Link
US (2) US6852732B2 (xx)
EP (1) EP1299378B1 (xx)
JP (1) JP2004502685A (xx)
KR (1) KR20030015368A (xx)
CN (2) CN1535968A (xx)
AR (1) AR028782A1 (xx)
AT (1) ATE353885T1 (xx)
AU (2) AU2001269437B2 (xx)
BG (1) BG107374A (xx)
BR (1) BR0112166A (xx)
CA (1) CA2412287A1 (xx)
CZ (1) CZ20024229A3 (xx)
DE (1) DE60126616T2 (xx)
EA (1) EA005289B1 (xx)
EE (1) EE200300007A (xx)
HK (1) HK1057042A1 (xx)
HR (1) HRP20030074A2 (xx)
HU (1) HUP0301165A2 (xx)
IL (1) IL153718A0 (xx)
MX (1) MXPA02012820A (xx)
NO (1) NO20026125L (xx)
PL (1) PL358411A1 (xx)
SK (1) SK132003A3 (xx)
TW (1) TW591022B (xx)
WO (1) WO2002002549A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
EP1927594A1 (en) * 2003-01-14 2008-06-04 Arena Pharmaceuticals, Inc. 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MXPA06003762A (es) * 2003-10-16 2006-06-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de recaptacion de neurotransmisor monoamina y un inhibidor de acetilcolinesterasa.
WO2005063756A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US7557111B2 (en) * 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
JP4742273B2 (ja) * 2004-01-06 2011-08-10 大正製薬株式会社 ピロロピリミジン及びピロロトリアジン誘導体
DE602005000676T2 (de) 2004-01-06 2007-11-22 Taisho Pharmaceutical Co., Ltd. Triazacyclopenta[cd]indenderivate
JP2007526906A (ja) * 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
BRPI0512514A (pt) * 2004-06-25 2008-03-11 Taisho Pharmaceutical Co Ltd composto, antagonista para receptores de crf, e, uso de um composto
JP2007161585A (ja) * 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
EP1991531A1 (en) * 2006-02-28 2008-11-19 Amgen Inc. Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
EA200900960A1 (ru) * 2007-01-31 2010-02-26 Новартис Аг Производные пиперидинацетамида для лечения воспалительных или аллергических заболеваний
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
CA2833209C (en) 2007-04-27 2016-06-28 Purdue Pharma L.P. Piperidine and piperazine compounds as trpv1 antagonists
US8389549B2 (en) 2007-04-27 2013-03-05 Purdue Pharma L.P. Substituted pyridines useful for treating pain
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
CN103402995B (zh) 2011-01-07 2016-08-31 大鹏药品工业株式会社 吲哚、吲唑衍生物或其盐
MX2013007938A (es) * 2011-01-07 2013-11-01 Taiho Pharmaceutical Co Ltd Compuesto biciclico novedoso o sal del mismo.
AR086709A1 (es) 2011-06-22 2014-01-15 Purdue Pharma Lp Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CA3023032A1 (en) * 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
EP3582772A1 (en) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
EP3838847B1 (en) 2019-12-20 2024-04-17 Industrial Technology Research Institute Composite material and method of removing fluorine in waste liquid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
ES2203937T3 (es) 1997-03-26 2004-04-16 Taisho Pharmaceutical Co., Ltd Derivados de 4-tetrahidropiridilpirimidina.
US6482836B1 (en) * 1997-04-22 2002-11-19 Charles Huang CRF antagonistic quino- and quinazolines
IL133800A0 (en) 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
JPH11335373A (ja) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd アリールメチレンピペリジノピリミジン誘導体
JPH11335376A (ja) 1998-05-25 1999-12-07 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
JP2000086663A (ja) * 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
AU756702B2 (en) 1999-03-11 2003-01-23 Taisho Pharmaceutical Co., Ltd. Carbamoyl tetrahydropyridine derivatives

Also Published As

Publication number Publication date
AU6943701A (en) 2002-01-14
PL358411A1 (en) 2004-08-09
MXPA02012820A (es) 2003-05-14
KR20030015368A (ko) 2003-02-20
CN1535968A (zh) 2004-10-13
EP1299378A4 (en) 2004-01-28
US7160900B2 (en) 2007-01-09
SK132003A3 (en) 2003-08-05
EE200300007A (et) 2004-08-16
CA2412287A1 (en) 2002-01-10
US20050009874A1 (en) 2005-01-13
EP1299378A1 (en) 2003-04-09
JP2004502685A (ja) 2004-01-29
CN1439001A (zh) 2003-08-27
EA005289B1 (ru) 2004-12-30
NO20026125D0 (no) 2002-12-19
NO20026125L (no) 2003-02-04
US6852732B2 (en) 2005-02-08
TW591022B (en) 2004-06-11
HRP20030074A2 (en) 2005-02-28
DE60126616D1 (de) 2007-03-29
BG107374A (bg) 2004-09-30
US20040034061A1 (en) 2004-02-19
CN1260225C (zh) 2006-06-21
EP1299378B1 (en) 2007-02-14
CZ20024229A3 (cs) 2003-06-18
WO2002002549A1 (en) 2002-01-10
BR0112166A (pt) 2003-09-02
IL153718A0 (en) 2003-07-06
AR028782A1 (es) 2003-05-21
AU2001269437B2 (en) 2005-12-01
ATE353885T1 (de) 2007-03-15
EA200300118A1 (ru) 2003-08-28
DE60126616T2 (de) 2007-10-25
HUP0301165A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
IL153718A0 (en) Tetrahydropyridino or piperidino heterocyclic derivatives
GB0030710D0 (en) Piperazine derivatives
AU8395501A (en) Piperazine derivatives
DZ3306A1 (fr) Derives de piperazine
IL182030A0 (en) Cyanopyrrolidine derivatives
HK1054042A1 (en) 2-Aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
GB0108099D0 (en) Aminopiperidine derivatives
GB0106177D0 (en) Piperazine derivatives
IL152177A0 (en) Piperazine and piperidine compounds
HK1061018A1 (en) Substituted c-cyclohexylmethylamine derivatives
IL152979A0 (en) Heterocyclic compounds
AU8993701A (en) Substituted 1-aminobutan-3-ol derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
IL155104A0 (en) 5-amino-1-pentene-3-ol substituted derivatives
HK1048117A1 (zh) 2-苯基吡喃-4-酮衍生物
GB0001972D0 (en) Heterocyclic derivatives
GB0001993D0 (en) Heterocyclic derivatives
GB0009452D0 (en) PTP1B-Inhibiting heterocyclic derivatives
GB0104583D0 (en) Piperidine derivatives
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
SI1322590T1 (sl) Substituirani 5-amino-1-penten-3-olni derivati
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100704